Claims
- 1. A compound of the formula (I):
- 2. A compound of the formula (I):
- 3. The compound of claim 2, wherein R1 represents a hydrogen atom or a chlorine atom.
- 4. The compound of claim 2, wherein R1 represents a chlorine atom.
- 5. The compound according to any one of claims 2 to 4, wherein R2 represents an alkyl group having from 1 to 6 carbon atoms, an aminocarbonyl group, or mono- or di-alkylaminocarbonyl group having from 1 to 6 carbon atoms.
- 6. The compound according to any one of claims 2 to 4, wherein R2 represents an alkyl group having from 1 to 6 carbon atoms.
- 7. The compound according to any one of claims 2 to 4, wherein R2 represents a methyl group or an ethyl group.
- 8. The compound according to any one of claims 2 to 7, wherein R3 represents an alkyl group having from 1 to 8 carbon atoms;
said alkyl group of R3 is substituted by at least one substituent selected from the group consisting of substituents α; said substituents α is aryl, hydroxy, oxo, aminocarbonyl, mono- or di-alkylaminocarbonyl having from 1 to 6 carbon atoms, alkylsulfonylamino having from 1 to 6 carbon atoms, heterocyclic, heterocycliccarbonyl, or cycloalkyl having from 3 to 8 carbon atoms; said heterocyclic and the heterocyclic moiety of said heterocycliccarbonyl, both of substituents α, are 5- to 7-membered cyclic groups containing from 1 to 3 heteroatoms selected from the group consisting of sulfur atoms, oxygen atoms and nitrogen atoms.
- 9. The compound according to any one of claims 2 to 7, wherein R3 represents an alkyl group having from 1 to 10 carbon atoms;
said alkyl group in R3 is substituted by at least one substituent selected from the group consisting of substituents α; said substituents α is aryl, hydroxy, oxo, alkylsulfonylamino having from 1 to 6 carbon atoms or heterocycliccarbonyl; the heterocyclic moiety of said heterocycliccarbonyl is piperidinyl or morpholinyl.
- 10. A compound according to claim 1 selected from
5-amino-6-chloro-N-{[1-(3,3-dimethyl-2-oxobutyl)piperidin-4-yl]methyl}-2-methylimidazo[1,2-a]pyridine-8-carboxamide; 5-amino-6-chloro-N-{[1-(2-hydroxy-3,3-dimethylbutyl)piperidin-4-yl]methyl}-2-methylimidazo[1,2-a]pyridine-8-carboxamide; 5-amino-6-chloro-2-ethyl-N-{[1-(3-morpholin-4-yl-3-oxopropyl)piperidin-4-yl]methyl}imidazo[1,2-a]pyridine-8-carboxamide; 5-amino-6-chloro-2-ethyl-N-{[1-(2-morpholin-4-yl-2-oxoethyl)piperidin-4-yl]methyl}imidazo[1,2-a]pyridine-8-carboxamide; 5-amino-6-chloro-N-{[1-(3,3-dimethyl-2-oxo-2-butyl)piperidin-4-yl]methyl}-2-ethylimidazo[1,2-a]pyridine-8-carboxamide; 5-amino-6-chloro-2-ethyl-N-{[1-(2-[(methylsulfonyl)amino]ethyl))piperidin-4-yl]]]methyl]imidazo[1,2-a]pyridine-8-carboxamide; 5-amino-6-chloro-2-ethyl-N-{[(1.2-hydroxy-2-methylpropyl)piperidin-4-yl]methyl}imidazo[1,2-a]pyridine-8-carboxamide; 5-amino-6-chloro-N-{[1-(2-hydroxy-2-methylpropyl)piperidin-4-yl]methyl}-2-methylimidazo[1,2-a]pyridine-8-carboxamide; 5-amino-6-chloro-2-ethyl-N-{[1-(4-hydroxy-3,3-dimethyl-2-oxobutyl)piperidin-4-yl]methyl}imidazo[1,2-a]pyridine-8-carboxamide; 5-amino-6-chloro-2-ethyl-N-{[1-(2-hydroxybutyl)piperidin-4-yl]methyl}imidazo[1,2-a]pyridine-8-carboxamide, half oxalate salt; and 5-amino-6-chloro-2-ethyl-N-{[1-(2-oxy-2-piperidin-1-ylethyl)piperidin-4-yl]methyl}imidazo[1,2-a]pyridine-8-carboxamide; or a pharmaceutically acceptable ester of such compound, or a pharmaceutically acceptable salt thereof.
- 11. A compound according to claim 1 selected from
5-amino-6-chloro-N-{[1-(3,3-dimethyl-2-oxo-2-butyl)piperidin-4-yl]methyl}-2-ethylimidazo[1,2-a]pyridine-8-carboxamide; 5-amino-6-chloro-2-ethyl-N-{[1-(2-[(methylsulfonyl)amino]ethyl))piperidin-4-yl]]]methyl]imidazo[1,2-a]pyridine-8-carboxamide; 5-amino-6-chloro-2-ethyl-N-{[(1-(2-hydroxy-2-methylpropyl)piperidin-4-yl]methyl}imidazo[1,2-a]pyridine-8-carboxamide; 5-amino-6-chloro-N-{[1-(2-hydroxy-2-methylpropyl)piperidin-4-yl]methyl}-2-methylimidazo[1,2-a]pyridine-8-carboxamide; 5-amino-6-chloro-2-ethyl-N-{[1-(4-hydroxy-3,3-dimethyl-2-oxobutyl)piperidin-4-yl]methyl}imidazo[1,2-a]pyridine-8-carboxamide; 5-amino-6-chloro-2-ethyl-N-{[1-(2-hydroxybutyl)piperidin-4-yl]methyl}imidazo[1,2-a]pyridine-8-carboxamide, half oxalate salt; and 5-amino-6-chloro-2-ethyl-N-{[1-(2-oxy-2-piperidin-1-ylethyl)piperidin-4-yl]methyl}imidazo[1,2-a]pyridine-8-carboxamide; or a pharmaceutically acceptable ester of such compound. or a pharmaceutically acceptable salt thereof.
- 12. A pharmaceutical composition for the treatment or prevention of gastroesophageal reflux disease, gastrointestinal disease, gastric motility disorder, upper gut motility disorder, non-ulcer dyspepsia, functional dyspepsia, irritable bowel syndrome, constipation, dyspepsia, esophagitis, gastroesophageral disease, nausea, central nervous system disease, alzheimers disease, cognitive disorder, emesis, migraine, neurological disease, pain, ischaemic stroke, anxiety or cardiovascular disorder, which comprises a therapeutically effective amount of a compound of the formula (I):
- 12. A method for the treatment or prevention of disease conditions mediated by 5-HT4 receptor activity, in a mammalian subject, which comprises administering to said subject a therapeutically effective amount of a compound of the formula (I):
- 13. A method for the treatment or prevention of gastroesophageal reflux disease, gastrointestinal disease, gastric motility disorder, upper gut motility disorder, non-ulcer dyspepsia, functional dyspepsia, irritable bowel syndrome, constipation, dyspepsia, esophagitis, gastroesophageral disease, nausea, central nervous system disease, alzheimers disease, cognitive disorder, emesis, migraine, neurological disease, pain, ischaemic stroke, anxiety or cardiovascular disorder, which comprises administering to said subject a therapeutically effective amount of a compound of the formula (I):
RELATED APPLICATIONS
[0001] This application claims benefit of priority under 35 U.S.C 119(e) to U.S. Provisional Application No. 60/412,426 filed on Sep. 20, 2002, which is herein incorporated in its entirety by reference.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60412426 |
Sep 2002 |
US |